biosimilar, biosimilar drug development, biosimilar perspectives, industry, intelligence

Download ebook: Biosimilar Industry Intelligence – 5 Key Perspectives

Change in the biosimilars industry is really picking up pace. The regulatory environment is becoming ever more stable and organisations are continuing to explore development, clinical and commercial strategies that offer genuine value to them, healthcare providers and most importantly, the patient. It is a busy time for the industry, but it is important to know the latest regulatory and industry developments, realise the …

Generic, Industry,

Where is the Generic Industry Heading?

At the World Generic Medicines Congress Europe 2014, Dr Gyorgy Thaler, Director of Development, Gedeon Richter gave a presentation entitled “Where is the (Generic) Industry Heading?” The presentation expresses Thaler’s belief that the generic industry needs to re-invent itself , a new message needs to be created: What do we bring to the patients? Why do they need us? How can …

compliance, cee, europe, regulation, pharma, pharmaceutical, industry, interview, ebook

Download ebook: Compliance Challenges & Conclusions

Predictions and tips to benchmark and drive your compliance programme CEE is regarded as a strong growth market for pharma, but operating in the region comes with its own challenges. In an era of changing social environment and a growing demand for increasing transparency, compliance faces a raft of challenges in this region including working with distributors, managing risk, understanding local …

Vbook: How can the industry work with payers to ensure that the best treatments get to patients?

      Ensuring that your medicines get to the patients that need them involves dealing with clinicians, payers, HTA bodies and internal and external stakeholders. Just as you think you understand the rules of the game, they change. We asked a number of acknowledged thought leaders their view on the fundamental question confronting the industry: How can we work …

Why orphan drugs are a key part of pharma’s future?

Back in the 1980's when the Orphan Drug Act was created, legislators, government agencies and even industry weren't expecting that it would create a multi-billion dollar market where companies now fight fiercely for a share in this segment. It's also understood that the timing of the Act was very fortuitous as it was closely aligned with the beginning of US' …